NO20043483L - Anvendelse av melagatran for fremstilling av et medikament for behandling av type 1 Diabetes mellitus - Google Patents
Anvendelse av melagatran for fremstilling av et medikament for behandling av type 1 Diabetes mellitusInfo
- Publication number
- NO20043483L NO20043483L NO20043483A NO20043483A NO20043483L NO 20043483 L NO20043483 L NO 20043483L NO 20043483 A NO20043483 A NO 20043483A NO 20043483 A NO20043483 A NO 20043483A NO 20043483 L NO20043483 L NO 20043483L
- Authority
- NO
- Norway
- Prior art keywords
- melagatran
- drug
- manufacture
- treatment
- type
- Prior art date
Links
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 title 1
- 229940079593 drug Drugs 0.000 title 1
- 239000003814 drug Substances 0.000 title 1
- 238000004519 manufacturing process Methods 0.000 title 1
- DKWNMCUOEDMMIN-PKOBYXMFSA-N melagatran Chemical compound C1=CC(C(=N)N)=CC=C1CNC(=O)[C@H]1N(C(=O)[C@H](NCC(O)=O)C2CCCCC2)CC1 DKWNMCUOEDMMIN-PKOBYXMFSA-N 0.000 title 1
- 229960002137 melagatran Drugs 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/55—Protease inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/37—Digestive system
- A61K35/39—Pancreas; Islets of Langerhans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/397—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having four-membered rings, e.g. azetidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/05—Dipeptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Gastroenterology & Hepatology (AREA)
- Cell Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Diabetes (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Virology (AREA)
- Zoology (AREA)
- Biotechnology (AREA)
- Developmental Biology & Embryology (AREA)
- Physiology (AREA)
- Biomedical Technology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Nutrition Science (AREA)
- Emergency Medicine (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Endocrinology (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| SE0200198A SE0200198D0 (sv) | 2002-01-23 | 2002-01-23 | New use |
| PCT/SE2003/000087 WO2003061682A1 (en) | 2002-01-23 | 2003-01-21 | The use of melagatran for the manufacture of a medicament for the treatment of type 1 diabetes mellitus |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NO20043483L true NO20043483L (no) | 2004-08-20 |
Family
ID=20286751
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO20043483A NO20043483L (no) | 2002-01-23 | 2004-08-20 | Anvendelse av melagatran for fremstilling av et medikament for behandling av type 1 Diabetes mellitus |
Country Status (14)
| Country | Link |
|---|---|
| US (2) | US7045502B2 (https=) |
| EP (1) | EP1469874A1 (https=) |
| JP (1) | JP2005516035A (https=) |
| KR (1) | KR20040075096A (https=) |
| CN (1) | CN100430089C (https=) |
| BR (1) | BR0306798A (https=) |
| CA (1) | CA2472241A1 (https=) |
| IL (1) | IL162853A0 (https=) |
| MX (1) | MXPA04007192A (https=) |
| NO (1) | NO20043483L (https=) |
| NZ (1) | NZ533749A (https=) |
| SE (1) | SE0200198D0 (https=) |
| WO (1) | WO2003061682A1 (https=) |
| ZA (1) | ZA200405342B (https=) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SE0200198D0 (sv) * | 2002-01-23 | 2002-01-23 | Astrazeneca Ab | New use |
| CN102918034B (zh) | 2010-03-30 | 2015-06-03 | 维颂公司 | 多取代芳族化合物作为凝血酶的抑制剂 |
| LT2968297T (lt) | 2013-03-15 | 2019-01-10 | Verseon Corporation | Multipakeistieji aromatiniai junginiai kaip serino proteazės inhibitoriai |
| ES2791749T3 (es) | 2013-03-15 | 2020-11-05 | Verseon Corp | Halogenopirazoles como inhibidores de la trombina |
| CN106687445A (zh) | 2014-09-17 | 2017-05-17 | 维颂公司 | 作为丝氨酸蛋白酶抑制剂的吡唑基取代的吡啶酮化合物 |
| RU2017131562A (ru) | 2015-02-27 | 2019-03-27 | Версеон Корпорейшн | Замещенные пиразольные соединения как ингибиторы сериновых протеаз |
| WO2020014669A1 (en) | 2018-07-13 | 2020-01-16 | Verseon Corporation | Thrombin inhibitors, formulations, and uses thereof |
| JP2024535677A (ja) | 2021-08-11 | 2024-10-02 | サナ バイオテクノロジー，インコーポレイテッド | 即時血液媒介性炎症反応を減少させるための同種細胞療法を目的とした遺伝子改変細胞 |
| EP4479416A1 (en) | 2022-02-17 | 2024-12-25 | Sana Biotechnology, Inc. | Engineered cd47 proteins and uses thereof |
| AU2024264889A1 (en) | 2023-05-03 | 2025-11-13 | Sana Biotechnology, Inc. | Methods of dosing and administration of engineered islet cells |
| EP4716541A2 (en) | 2023-05-22 | 2026-04-01 | Sana Biotechnology, Inc. | Methods of delivery of islet cells and related methods |
| WO2025043172A1 (en) | 2023-08-23 | 2025-02-27 | Sana Biotechnology, Inc. | Modified cd47 proteins and their uses |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SE9301916D0 (sv) | 1993-06-03 | 1993-06-03 | Ab Astra | New peptides derivatives |
| TWI238827B (en) | 1995-12-21 | 2005-09-01 | Astrazeneca Ab | Prodrugs of thrombin inhibitors |
| SE9900070D0 (sv) * | 1999-01-13 | 1999-01-13 | Astra Ab | New use |
| SE523817C2 (sv) | 1999-02-05 | 2004-05-18 | Corline Systems Ab | Användning av ett koagulationsförebyggande ämne i samband med transplantation av insulinproducerande celler |
| US6462021B1 (en) | 2000-11-06 | 2002-10-08 | Astrazeneca Ab | Use of low molecular weight thrombin inhibitor |
| SE0200198D0 (sv) * | 2002-01-23 | 2002-01-23 | Astrazeneca Ab | New use |
-
2002
- 2002-01-23 SE SE0200198A patent/SE0200198D0/xx unknown
-
2003
- 2003-01-21 CN CNB038026740A patent/CN100430089C/zh not_active Expired - Fee Related
- 2003-01-21 US US10/502,069 patent/US7045502B2/en not_active Expired - Fee Related
- 2003-01-21 IL IL16285303A patent/IL162853A0/xx unknown
- 2003-01-21 CA CA002472241A patent/CA2472241A1/en not_active Abandoned
- 2003-01-21 WO PCT/SE2003/000087 patent/WO2003061682A1/en not_active Ceased
- 2003-01-21 BR BR0306798-0A patent/BR0306798A/pt not_active IP Right Cessation
- 2003-01-21 EP EP03701203A patent/EP1469874A1/en not_active Withdrawn
- 2003-01-21 NZ NZ533749A patent/NZ533749A/en unknown
- 2003-01-21 KR KR10-2004-7011228A patent/KR20040075096A/ko not_active Withdrawn
- 2003-01-21 JP JP2003561625A patent/JP2005516035A/ja active Pending
- 2003-01-21 MX MXPA04007192A patent/MXPA04007192A/es unknown
-
2004
- 2004-07-05 ZA ZA2004/05342A patent/ZA200405342B/en unknown
- 2004-08-20 NO NO20043483A patent/NO20043483L/no not_active Application Discontinuation
-
2006
- 2006-02-24 US US11/362,890 patent/US20060148720A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| IL162853A0 (en) | 2005-11-20 |
| CN100430089C (zh) | 2008-11-05 |
| ZA200405342B (en) | 2005-09-28 |
| MXPA04007192A (es) | 2004-10-29 |
| NZ533749A (en) | 2006-02-24 |
| SE0200198D0 (sv) | 2002-01-23 |
| US20050090424A1 (en) | 2005-04-28 |
| EP1469874A1 (en) | 2004-10-27 |
| JP2005516035A (ja) | 2005-06-02 |
| US20060148720A1 (en) | 2006-07-06 |
| CN1729010A (zh) | 2006-02-01 |
| WO2003061682A1 (en) | 2003-07-31 |
| US7045502B2 (en) | 2006-05-16 |
| KR20040075096A (ko) | 2004-08-26 |
| CA2472241A1 (en) | 2003-07-31 |
| BR0306798A (pt) | 2004-12-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NO20053041D0 (no) | Behandling av diabetes. | |
| IL213806A0 (en) | Use of derivatives of n-phenylpiperazin-1-yl-acetamide for the preparation of a pharmaceutical compositions for treatment of diabetes related conditions | |
| EP1477403A4 (en) | MEDICINES SUPPLY | |
| NO20020764L (no) | Benzosyrederivater for behandling av diabetes mellitus | |
| IL166058A0 (en) | Novel thiophenylglycoside derivatives methods for production thereof medicaments comprising said compounds and use thereof | |
| PL372865A1 (en) | Aryl 5-thio-beta-d-glucopyranoside derivatives and remedies for diabetes containing the same | |
| NO20043000L (no) | Et preparat for behandling av nevrocerebrovaskulaere sykdommer | |
| PL370818A1 (en) | Dosage form for treatment of diabetes mellitus | |
| IL210046A0 (en) | Ccr1 antagonists for the treatment of i.a. demyelinating inflammatory disease | |
| NO20022087D0 (no) | Fremgangsmåte for behandling av diabetes | |
| AU2003279442A8 (en) | 2-thiohydantoine derivative compounds and use thereof for the treatment of diabetes | |
| PL377164A1 (pl) | Pochodne anilinopirazolu przydatne do leczenia cukrzycy | |
| NO20043483L (no) | Anvendelse av melagatran for fremstilling av et medikament for behandling av type 1 Diabetes mellitus | |
| AU2003243708A1 (en) | Use of bases for the manufacture of a medicament in the treatment of different forms of inflammatory dermatosis | |
| IT1318514B1 (it) | Formulazioni contenenti un farmaco glucocorticosteroide per iltrattamento di patologie broncopolmonari. | |
| AU2003252182A1 (en) | Therapeutic treatment for the metabolic syndrome and type 2 diabetes | |
| AU2003303217A1 (en) | Use of substituted 2,5-diamidoindoles for the treatment of urological diseases | |
| AU2003223780A1 (en) | Treatment for pompe disease | |
| NO20032006L (no) | Anvendelse av melagatran for fremstilling av et medikament for behandling av ischemiske lidelser | |
| IL162509A (en) | Use of deoxypeganine for the production of a drug for treating clinical depression | |
| AU2003296545A1 (en) | Use of a trpm8-activating substance for the treatment of tumours | |
| NO20025883D0 (no) | Tiazolidinonsalt for behandling av diabetes mellitus | |
| AU2003294952A8 (en) | 3,3-dimethyl-8-oxoisoquinolines for medical purposes, methods for the production thereof, medicaments containing said compounds and the use of the same | |
| AU2002307327A1 (en) | Use of an ampa receptor potentiator for the manufacture of a medicament for the treatment of type 2 diabetes | |
| GB0212790D0 (en) | Medicament for the treatment of diabetes |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FC2A | Withdrawal, rejection or dismissal of laid open patent application |